Browse By: Country ι Category ι Tag
Home  »  JustPharmaReports.com

JustPharmaReports.com Market Research Reports

Publications by Justpharmareports provide clear, comprehensive, up-to-date, practical information and analyses on pricing/ reimbursement and medicines’ distribution for the industry professional. Researched and written exclusively by Donald Macarthur, probably the world\'s most experienced author of reports on the global pharmaceutical business environment, with more than 70 major titles over 25 years to his name, the detailed but readable texts will save $000s in consultants\' fees alone.


Pricing of Medical Devices, Diagnostics & Medical Equipment in Japan
With sales of almost USD 30 billion, Japan is the world’s second-largest market for medical devices and in vitro diagnostics, with the highest per capita outlay on such products in Asia. Device companies from overseas have been notably successful in Japan, but the prospects for further growth remain strong. The ageing population, a demand for the latest technology, fee-for-service service reimbursement and patient expectation are among the drivers. To fully enter the Japanese device or diagnostics market, achieving reimbursement under National Health Insurance (NHI) is almost mandatory. The access pathway is challenging to navigate and the rules are difficult to interpret. Now, for the first time in any publication, the system is explained is easy-to-follow English.   
Published Date: May 2014
Published By: JustPharmaReports.com

Price: $1509
Pharmaceutical Pricing & Distribution in Japan, 2014 Update
An industry insider described the negotiations with the Japanese government for the 2014 biennial pricing reform as tough. Yet the end result was clearly favourable to research-based companies. The system - while complex - remains timely, transparent, equitable, relatively stable and above all predictable. Launch prices are high by international standards and there are few prescribing or reimbursement barriers. More and more innovative brands are also retaining their prices during patent life. Japan is a must for any serious biopharmaceutical company to penetrate. But first you need to know the rules. This latest, fully-updated and greatly enlarged report from a critically-acclaimed series is the most comprehensive English-language text on optimising market access and life cycle managem
Published Date: May 2014
Published By: JustPharmaReports.com

Price: $1492
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of clinical and cost effectiveness? Payers are becoming increasingly strict. Four of the first seven orphan drugs to enter Germany’s AMNOG procedure were considered to bring only minor additional benefit and for two others the benefit was deemed non-quantifiable. Discounts were required for all. Re-evaluation by the Transparency Commission in France has seen bo
Published Date: Oct 2013
Published By: JustPharmaReports.com

Price: $2350
Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide
Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effectiveness), budget impact and/or utilisation to optimise performance, whilst at the same time allowing patient access. For many products considered costly they are almost essential to achieve reimbursement where health technology assessment is applied. Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide covers all the main types of agreements (finance-based, outcome- or performance-based, and compliance-based) and their many variants in all countries that employ th
Published Date: Feb 2013
Published By: JustPharmaReports.com

Price: $1050
Pharmaceutical Pricing & Distribution in Japan, 2012 Update
No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.  No new brand can be introduced without a yakka (reimbursement price) set by the  government. Innovative drugs receive price premiums while others are capped at the price of  older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere.  Big selling brands are repriced. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders This latest, fully-updated and en
Published Date: Jun 2012
Published By: JustPharmaReports.com

Price: $1400
Biosimilars: Current Situation & Future Prospects, Worldwide
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory pathway. Funds are flowing into the sector and many new partnership agreements signed. Everything in the biosimilar garden might look rosy, but what is the reality?  Biosimilar sales of $16+ billion were forecast in the EU and US alone for 2011.This estimate turned out to be 50-times too high. Does publication of the long-awaited guidance on the US Biologics Price Competition and Innovation Act mean a new daw
Published Date: Mar 2012
Published By: JustPharmaReports.com

Price: $3000
Pharmaceutical Pricing & Distribution in Japan, 2010 Update
The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing better’. His new report packs all the essentials needed to optimise market access and life cycle management into 60 pages and offers tremendous value. Completely updated, it explains all the latest changes to the NHI pricing rules, including the important new price premium for developing new drugs/new indications. New drug pricing and price revision processes made completely clear, with all formulae used and many up-to-date examples Incorporates all pricing rule changes coming into effect from April 2010 with forecast of further reforms in FY 2012 Written by an acknowledged
Published Date: Oct 2011
Published By: JustPharmaReports.com

Price: $760
Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget limitations, and growing demands for evidence of clinical and cost effectiveness?  The orphan drug Regulation 141/2000, resulting in 724 designated products and 62 marketing approvals in the first 10 years, has certainly been one of the most successful legislative measures by the EU. Encouraging development and accelerating regulatory approval are very important, but alone do not ensure orphan drugs
Published Date: Jun 2011
Published By: JustPharmaReports.com

Price: $2300
Market Access Korea: Breaking into the Developed World\'s Fastest Growing Pharmaceutical Market
South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market for medicines in the world. Currently ranked fourth in Asia-Pacific - after Japan, China and India, but ahead of Australia - drug sales at manufacturer selling prices are the equivalent of USD 11 billion. If you consider that foreign innovative products did not gain access to the reimbursement system until late 1999 it is remarkable that multinational companies today hold half of the top-10 sale
Published Date: Nov 2010
Published By: JustPharmaReports.com

Price: $1380
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other four Asia-Pacific countries also implementing orphan-promoting measures ahead of the EU.  Rare diseases are collectively not that rare, indeed 6-10% of people will suffer from one at some point in life. Asia-Pacific contains nearly two-thirds of the world’s population, and should offer great p
Published Date: Feb 2010
Published By: JustPharmaReports.com

Price: $2320

Back To Top